Catalyst Pharmaceuticals Downgraded Following $4.1B Acquisition Deal

Catalyst Pharmaceuticals has reached a definitive agreement to be acquired by Italy-based Angelini Pharma in an all-cash transaction valued at approximately $4.10 billion. Under the terms of the deal, shareholders are set to receive $31.50 per share, representing a 28% premium over the 30-day volume-weighted average price. Following the announcement, Oppenheimer downgraded CPRX from Outperform to Perform, noting that the fixed offer price effectively caps further upside potential for the stock. Meanwhile, law firm Halper Sadeh LLC has launched an investigation into the fairness of the transaction price on behalf of investors. This acquisition marks a significant strategic entry into the U.S. market for Angelini Pharma. Consequently, market analysts expect the stock to trade close to the acquisition price until the deal's completion.